| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1365-2141.2006.06018.X |
| P8608 | Fatcat ID | release_6qi36egz65gc5d3sx5n26pfc74 |
| P698 | PubMed publication ID | 16643427 |
| P5875 | ResearchGate publication ID | 7138646 |
| P50 | author | David Keeling | Q45869553 |
| P2093 | author name string | Henry Watson | |
| Simon Davidson | |||
| Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology | |||
| P2860 | cites work | The epitope specificity of heparin-induced thrombocytopenia | Q33497214 |
| Cross-reactivity study of low molecular weight heparins and heparinoid in heparin-induced thrombocytopenia | Q33497633 | ||
| The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia | Q33500949 | ||
| Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study | Q33504870 | ||
| High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. | Q53778782 | ||
| Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. | Q55034167 | ||
| Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban | Q31930059 | ||
| Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia | Q32110828 | ||
| Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia | Q33329275 | ||
| Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators. | Q33329695 | ||
| Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients | Q33333084 | ||
| Acute heparin-induced thrombocytopenia type II during cardiopulmonary bypass | Q33333089 | ||
| Management of urgent high-risk cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and coexisting disorders of renal function: use of heparin and epoprostenol combined with on-line monitoring of platelet function | Q33333092 | ||
| Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy | Q33334262 | ||
| Temporal aspects of heparin-induced thrombocytopenia | Q33337021 | ||
| Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo cross-reactivity with danaparoid and successful treatment with r-Hirudin | Q33338766 | ||
| Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. | Q33340362 | ||
| Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin | Q33343961 | ||
| Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia | Q33344216 | ||
| The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study | Q33345667 | ||
| Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series | Q33346170 | ||
| Heparin‐induced thrombocytopenia: pathogenesis and management | Q33348049 | ||
| Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. | Q33357246 | ||
| An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients | Q33357520 | ||
| Treatment of heparin-induced thrombocytopenia: a critical review | Q33359690 | ||
| Bivalent direct thrombin inhibitors: hirudin and bivalirudin | Q33361074 | ||
| Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies | Q33361860 | ||
| Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia | Q33362100 | ||
| Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q33362744 | ||
| Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia | Q33364229 | ||
| The pathophysiology of heparin-induced thrombocytopenia: biological basis for treatment | Q33364938 | ||
| New approaches to the diagnosis of heparin-induced thrombocytopenia | Q33364946 | ||
| Heparin-induced thrombocytopenia in neurologic patients treated with low-molecular-weight heparin | Q33365799 | ||
| Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis | Q33367004 | ||
| Bivalirudin: a review | Q33367230 | ||
| The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study | Q33367395 | ||
| Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin | Q33367978 | ||
| Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? | Q33369345 | ||
| Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay | Q33492740 | ||
| Use of enoxaparin in patients with heparin-induced thrombocytopenia syndrome | Q33495995 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombocytopenia | Q585285 |
| P304 | page(s) | 259-269 | |
| P577 | publication date | 2006-05-01 | |
| P1433 | published in | British Journal of Haematology | Q4970200 |
| P1476 | title | The management of heparin-induced thrombocytopenia | |
| P478 | volume | 133 |
| Q35222417 | A comparison of enoxaparin with unfractionated heparins in patients with coronary heart disease in an emergency department in rural South Indian tertiary care teaching hospital |
| Q33380067 | Acute adrenal insufficiency associated with heparin-induced thrombocytopenia |
| Q38442992 | Anticoagulation in Chronic Hemodialysis: Progress Toward an Optimal Approach |
| Q33375570 | Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients |
| Q33394891 | Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic study |
| Q33402036 | Bleeding risk factors associated with argatroban therapy in the critically ill. |
| Q33376860 | Case studies in anticoagulation management |
| Q48162860 | Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial |
| Q33385883 | Compliance with platelet count monitoring recommendations and management of possible heparin-induced thrombocytopenia in hospitalized patients receiving low-molecular-weight heparin. |
| Q33405248 | Contributions of biological tests and the 4 Ts score in the diagnosis of heparin induced thrombocytopenia |
| Q83164270 | Diagnosing heparin induced thrombocytopenia in critically ill patients |
| Q33373700 | Direct thrombin inhibition during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia |
| Q33382034 | Dosing patterns and outcomes in African American, Asian, and Hispanic patients with heparin-induced thrombocytopenia treated with argatroban |
| Q33389900 | Emergency department awareness of heparin-induced thrombocytopenia: how frequently is risk assessment documented in patients with thrombosis? |
| Q33386621 | Fondaparinux for the treatment of acute heparin-induced thrombocytopenia: a single-center experience |
| Q33403703 | Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. |
| Q36143295 | Haematology and neurology |
| Q24647207 | Heparin induced thrombocytopenia: diagnosis and management update |
| Q33410083 | Heparin induced thrombocytopenia: review |
| Q33380320 | Heparin-induced thrombocytopenia during renal replacement therapy in the intensive care unit |
| Q33405846 | Heparin-induced thrombocytopenia following hip and knee arthroplasty |
| Q26751442 | Heparin-induced thrombocytopenia in solid organ transplant recipients: The current scientific knowledge |
| Q33378892 | Heparin-induced thrombocytopenia: 2008 update |
| Q33385560 | Heparin-induced thrombocytopenia: a renal perspective |
| Q26851799 | Heparin-induced thrombocytopenia: a review of concepts regarding a dangerous adverse drug reaction |
| Q33387039 | Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study |
| Q33384889 | Impact of renal function on argatroban therapy during percutaneous coronary intervention |
| Q33375535 | Latest medical treatment strategies for venous thromboembolism |
| Q33385745 | Low-molecular-weight heparin-induced skin necrosis: about 2 cases |
| Q33387758 | Mesenteric and coeliac occlusions following heparin-induced thrombocytopenia after aortobiprofunda bypass surgery |
| Q33392998 | On the use of prothrombin complex concentrate in patients with coagulopathy requiring tooth extraction |
| Q33394283 | Optimized alkylated cyclodextrin polysulphates with reduced risks on thromboembolic accidents improve osteoarthritic chondrocyte metabolism |
| Q24186811 | Pentasaccharides for the treatment of deep vein thrombosis |
| Q47376811 | Pentasaccharides for the treatment of deep vein thrombosis. |
| Q33376726 | Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia |
| Q33408404 | Platelet factor 4-positive thrombi adhering to the ventricles of a ventricular assist device in patients with heparin-induced thrombocytopenia type II. |
| Q36710996 | Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results |
| Q33400896 | Pre-emptive use of bivalirudin for emergent off-pump coronary artery bypass surgery in a suspected case of heparin-induced thrombocytopenia |
| Q37998007 | Pregnancy-associated venous thrombosis |
| Q33374563 | Prospective evaluation of the '4Ts' score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin-induced thrombocytopenia |
| Q33397294 | Rapid exclusion or confirmation of heparin-induced thrombocytopenia: a single-center experience with 1,291 patients |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q33383967 | Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia |
| Q33410242 | Refractoriness to platelet transfusion in acute myeloid leukemia correlated with the optical density of anti-platelet factor 4/heparin antibodies |
| Q33382275 | Review: recent advances in argatroban-warfarin transition in patients with heparin-induced thrombocytopenia |
| Q64985079 | Risk of Venous Thromboembolism in Patients With Keratinocyte Carcinoma. |
| Q38463548 | Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy |
| Q33380179 | Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series |
| Q43905870 | Superficial vein thrombosis |
| Q33376085 | The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia. |
| Q64248267 | Thrombocytopenia in the intensive care unit |
| Q33399094 | Thrombocytopenia in the intensive care unit |
| Q24200589 | Unfractionated heparin versus low molecular weight heparin for avoiding heparin-induced thrombocytopenia in postoperative patients |
| Q33441234 | Unfractionated heparin versus low molecular weight heparins for avoiding heparin-induced thrombocytopenia in postoperative patients. |
| Q37807917 | Venous thromboembolic prophylaxis for hip fractures |
| Q37137952 | Venous thromboembolism in hospitalised patients: a public health crisis? |
| Q33396089 | What are the anticoagulation options for intermittent hemodialysis? |
| Q33385554 | Woman anticoagulated with thrombotic ischemic phenomena in lower limbs |
Search more.